Tsujimoto, T., Yamamoto-Honda, R., Kajio, H., Kishimoto, M., Noto, H., Hachiya, R., Kimura, A., Kakei, M. and Noda, M. (2014) Vital Signs, QT Prolongation, and Newly Diagnosed Cardiovascular Disease during Severe Hypoglycemia in Type 1 and Type 2 Diabetic Patients. Diabetes Care, 37, 217-221.
http://dx.doi.org/10.2337/dc13-0701

has been cited by the following article:

• TITLE: Improved All Cause and Cardiovascular Mortality and Morbidity by Empagliflozin: Too Good to Be True!

  AUTHORS: Udaya M. Kabadi

  KEYWORDS: Review Paper

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.6 No.2, April 20, 2016

  ABSTRACT: It was interesting to read the recent article regarding the efficacy of Empagliflozin in reducing all cause and cardiovascular mortality [1]. Superficially, the report appears to be very promising. However, the methodology, the results and the conclusions deserve and need further scrutiny and validation for several reasons.